Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 12;11(5):397-398.
doi: 10.1093/ehjcvp/pvaf050.

Our knowledge about atrial fibrillation steadily increases

Stefan Agewall  1
Affiliations

Our knowledge about atrial fibrillation steadily increases

Stefan Agewall. Eur Heart J Cardiovasc Pharmacother. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: none declared.

Similar articles

See all similar articles

References

    1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992. - PubMed
    1. De Caterina R, Patti G, Westerbergh J, Horowitz J, Ezekowitz JA, Lewis BS, Lopes RD, McMurray JJV, Atar D, Bahit MC, Keltai M, López-Sendón JL, Ruzyllo W, Granger CB, Alexander JH, Wallentin L. Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother 2022;8:227–235. - PubMed
    1. Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Yeh YH, Kuo CT, See LC, Lip GYH. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 2023;9:681–691. - PubMed
    1. Lee S-R, Choi JM, Kwon S, Ahn H-J, Lee K-Y, Choi J-I, Lee SH, Heo JH, Oh I-Y, On YK, Yu HT, Lee K-N, Kim N-H, Park HW, Lee KH, Shin SY, Park H-S, Han S, Oh S, Lip GYH, Park J-S, Choi E-K; on behalf of the ASPIRE investigators. Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results. Eur Heart J Cardiovasc Pharmacother 2025;11:403–411. - PMC - PubMed
    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group . 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627–3639. - PubMed

LinkOut - more resources